title: High altitude, a natural research laboratory for the study of cardiovascular physiology and pathophysiology.
abstract: High altitude constitutes an exciting natural laboratory for medical research. Although initially, the aim of high-altitude research was to understand the adaption of the organism to hypoxia and find treatments for altitude-related diseases, during the past decade or so, the scope of this research has broadened considerably. Two important observations led the foundation for the broadening of the scientific scope of high-altitude research. First, high-altitude pulmonary edema represents a unique model that allows studying fundamental mechanisms of pulmonary hypertension and lung edema in humans. Second, the ambient hypoxia associated with high-altitude exposure facilitates the detection of pulmonary and systemic vascular dysfunction at an early stage. Here, we will review studies that, by capitalizing on these observations, have led to the description of novel mechanisms underpinning lung edema and pulmonary hypertension and to the first direct demonstration of fetal programming of vascular dysfunction in humans.
authors.affiliation: Department of Internal Medicine and the Botnar Center for Extreme Medicine, Centre Hospitalier Universitaire Vaudois, CH-1011 Lausanne, Switzerland. urs.scherrer@chuv.ch <urs.scherrer@chuv.ch>
authors.forename: Urs
authors.initials: U
authors.lastname: Scherrer
authors.forename: Yves
authors.initials: Y
authors.lastname: Allemann
authors.forename: Pierre-Yves
authors.initials: PY
authors.lastname: Jayet
authors.forename: Emrush
authors.initials: E
authors.lastname: Rexhaj
authors.forename: Claudio
authors.initials: C
authors.lastname: Sartori
mesh_terms: D000531:Altitude; D000532:Altitude Sickness / Q000150:complications / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology*; D000818:Animals; D035843:Biomedical Research; D002319:Cardiovascular System / Q000503:physiopathology*; D002986:Clinical Trials as Topic; D003907:Dexamethasone / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D054092:Foramen Ovale, Patent / Q000150:complications; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D006976:Hypertension, Pulmonary / Q000503:physiopathology*; D009569:Nitric Oxide / Q000096:biosynthesis; D018384:Oxidative Stress; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D011654:Pulmonary Edema / Q000503:physiopathology*; D012307:Risk Factors; D013564:Sympathetic Nervous System / Q000503:physiopathology; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use
chemical_list: D005938:Glucocorticoids; D010726:Phosphodiesterase Inhibitors; D014665:Vasodilator Agents; D009569:Nitric Oxide; D003907:Dexamethasone